DT56A
DT56A has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jun 22, 2026: “Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome”.
1 paper studies it2 findingsUpdated
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“whereas Femarelle® did not show significant changes over the 3-month period.”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave DT56A to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves climacteric symptoms no change: Has no effect on sexual function | Randomized trial3 months | 70 peopleWomenmean age: 53 yearsMidlife adults; Postmenopausal women | Gynecologic and obstetric investigation, Jun 22, 2026 |
What did studies of DT56A find?
2Studies of DT56A measured 2 outcomes; the most studied are sexual function (1 study) and climacteric symptoms (1).
Sexual function
no changein humans1
1 study
Sexual function
no changein humans1
DT56A showed no clear effect on sexual function in humans.
“whereas Femarelle® did not show significant changes over the 3-month period.”
Human trial644 mg/day3 monthsfemales
Gynecologic and obstetric investigation
Climacteric symptoms
upin humans1
1 study
Climacteric symptoms
upin humans1
DT56A improves climacteric symptoms in humans.
“Both DHEA and Femarelle® demonstrated comparable efficacy in reducing total Greene Climacteric Scale scores.”
Human trial644 mg/day3 monthsfemales
Gynecologic and obstetric investigation